Telomir extends runway to Q1 2027, announces TELI merger, but pushes IND filing into 2026

Filed March 17, 2026 · Period ending December 31, 2025 · Compared to 10-K Feb 4, 2025 · ~2 min read

Key Changes

• high

  Company announced merger with TELI Pharmaceuticals to consolidate worldwide IP rights for Telomir-1. TELI shareholders receive 1:1 stock exchange, resulting in ~50/50 ownership split and significant dilution for current TELO holders. CEO owns 23% of TELI; conflicts of interest disclosed.

  Business: TELI merger agreement view on EDGAR →
• high

  IND submission timeline slipped from Q4 2025 to sometime in 2026, with first-in-human trials pushed to an unspecified date after IND effectiveness. Company added explicit risk language about potential FDA requests for additional studies.

  Business: IND submission timeline view on EDGAR →
• high

  Cash position improved from $1.3M to $7.3M through $9.7M in equity financings (Bayshore $3M direct investment at 18% premium, plus $6.5M ATM proceeds). Operating runway extended from mid-Q2 2025 to Q1 2027; going-concern doubt removed.

  MD&A: Cash position and runway verify on EDGAR →